4//SEC Filing
Zydowsky Lynne 4
Accession 0000899243-20-035267
CIK 0001445283other
Filed
Dec 27, 7:00 PM ET
Accepted
Dec 28, 7:10 PM ET
Size
8.9 KB
Accession
0000899243-20-035267
Insider Transaction Report
Form 4
Zydowsky Lynne
Director
Transactions
- Award
Stock Option (Right to Buy)
2020-12-22+12,495→ 12,495 totalExercise: $8.16Exp: 2029-12-15→ Common Stock (12,495 underlying) - Award
Stock Option (Right to Buy)
2020-12-22+5,271→ 5,271 totalExercise: $8.16Exp: 2030-04-06→ Common Stock (5,271 underlying)
Footnotes (5)
- [F1]On August 22, 2020, the Issuer (formerly known as Proteostasis Therapeutics, Inc.) entered into an Agreement and Plan of Merger and Reorganization, as amended on November 6, 2020, with Pangolin Merger Sub, Inc. ("Merger Sub"), Yumanity, Inc. (formerly known as Yumanity Therapeutics, Inc.) and Yumanity Holdings, LLC ("Holdings"). On December 22, 2020, Merger Sub was merged with and into Yumanity, Inc., with Yumanity, Inc. surviving as a wholly-owned subsidiary of the Issuer (the "Merger"). Immediately prior to the consummation of the Merger, Holdings was merged with and into Yumanity, Inc., with Yumanity, Inc. as the surviving entity.
- [F2]The shares subject to the option vest in equal quarterly installments over four years, commencing on October 1, 2019.
- [F3]Received in the Merger in exchange for a stock option to acquire 59,266 shares of Yumanity, Inc. common stock for $1.72 per share.
- [F4]The shares subject to the option vest in equal quarterly installments over four years, commencing on February 18, 2020.
- [F5]Received in the Merger in exchange for a stock option to acquire 25,000 shares of Yumanity, Inc. common stock for $1.72 per share.
Documents
Issuer
YUMANITY THERAPEUTICS, INC.
CIK 0001445283
Entity typeother
Related Parties
1- filerCIK 0001835169
Filing Metadata
- Form type
- 4
- Filed
- Dec 27, 7:00 PM ET
- Accepted
- Dec 28, 7:10 PM ET
- Size
- 8.9 KB